Monomethyl fumarate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Monomethyl fumarate
Accession Number
DB14219
Description
Not Available
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Structure
Thumb
Weight
Average: 130.099
Monoisotopic: 130.026608673
Chemical Formula
C5H6O4
Synonyms
  • Fumaric acid monomethyl ester
  • Methyl hydrogen fumarate
  • MMF

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Monomethyl fumarate.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Monomethyl fumarate.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Monomethyl fumarate.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Monomethyl fumarate.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Monomethyl fumarate.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Monomethyl fumarate.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Monomethyl fumarate.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Monomethyl fumarate.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Monomethyl fumarate.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Monomethyl fumarate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BafiertamCapsule95 mg/1OralBanner Life Sciences LLC2020-04-28Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as fatty acid esters. These are carboxylic ester derivatives of a fatty acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acid esters
Direct Parent
Fatty acid esters
Alternative Parents
Unsaturated fatty acids / Dicarboxylic acids and derivatives / Methyl esters / Enoate esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Aliphatic acyclic compound / Alpha,beta-unsaturated carboxylic ester / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Enoate ester / Fatty acid ester / Hydrocarbon derivative
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
45IUB1PX8R
CAS number
2756-87-8
InChI Key
NKHAVTQWNUWKEO-NSCUHMNNSA-N
InChI
InChI=1S/C5H6O4/c1-9-5(8)3-2-4(6)7/h2-3H,1H3,(H,6,7)/b3-2+
IUPAC Name
(2E)-4-methoxy-4-oxobut-2-enoic acid
SMILES
COC(=O)\C=C\C(O)=O

References

General References
Not Available
ChemSpider
4520322
BindingDB
50342426
RxNav
1546433
ChEMBL
CHEMBL589586
ZINC
ZINC000004416885

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDisseminated Sclerosis1
1CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral95 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US9511043No2015-02-272035-02-27US flag
US9326965No2015-02-272035-02-27US flag
US9814692No2015-02-272035-02-27US flag
US9636318No2015-02-272035-02-27US flag
US9814691No2015-02-272035-02-27US flag
US10105336No2015-02-272035-02-27US flag
US9820961No2015-02-272035-02-27US flag
US10098863No2015-02-272035-02-27US flag
US9566259No2015-02-272035-02-27US flag
US9636319No2015-02-272035-02-27US flag
US10105337No2015-02-272035-02-27US flag
US9326947No2015-02-272035-02-27US flag
US9820960No2015-02-272035-02-27US flag
US9517209No2015-02-272035-02-27US flag
US10105335No2015-02-272035-02-27US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility40.1 mg/mLALOGPS
logP0.39ALOGPS
logP0.34ChemAxon
logS-0.51ALOGPS
pKa (Strongest Acidic)3.12ChemAxon
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity29.38 m3·mol-1ChemAxon
Polarizability11.61 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on July 04, 2018 15:10 / Updated on September 06, 2020 08:37

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates